Peer Reviewed Alzheimer's
Vision - To address the long-term consequences of traumatic brain injury as they pertain to Alzheimer’s disease and Alzheimer’s disease related dementias
Military personnel and other individuals living with traumatic brain injury (TBI) face an increased risk for developing several long-term health problems. These include Alzheimer’s-like dementia, aggression, memory loss, depression, and symptoms similar to those of other neurological diseases. The PRARP (formerly the Militarily Relevant Peer Reviewed Alzheimer’s Disease Research Program) was initiated in 2011 to address the long-term consequences of TBI as they pertain to Alzheimer’s disease (AD). In FY16, the program was expanded to include AD-related dementias (ADRD) research as it pertains to TBI.
Consistent with the PRARP's mission and vision, the program faces 6 overarching challenges for FY20. These overarching challenges represent longstanding research goals for the program:
- Foundational Research: Research to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities and to translate these findings.
- Paucity of Clinical Studies: The paucity of clinical studies to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities.
- Diagnostics and Prognostics: The need for technologies, tests, surveys, questionnaires, devices, biomarkers, or analyses to detect TBI sequelae for AD/ADRD utilizing new and/or pre-existing datasets.
- Epidemiology: The paucity of epidemiological research to examine the interrelationship between TBI, risk and resiliency factors, and subsequent AD/ADRD for the military, Veteran, and civilian communities.
- Quality of Life: The need for technologies, assessments, interventions, or devices to benefit individuals living with the common symptoms of TBI and AD/ADRD.
- Family and Care Support: The need for technologies, assessments, interventions, or devices that enhance the lives of those providing care and families of individuals living with the common symptoms of TBI and/or AD/ADRD.
The PRARP has identified 8 research focus areas which are viewed as avenues towards addressing the FY20 PRARP Overarching Challenges. These are technical in nature, and represent research disciplines most suited to the PRARP's overarching challenges:
- Mechanisms of Pathogenesis: Identification of contributing mechanisms to include circuit dysfunction associated with TBI and subsequent AD/ADRD.
- Biomarkers: Development of methods to diagnose, prognose, or characterize neurological changes or risk/resiliency factors associated with TBI and subsequent AD/ADRD.
- Quality of Life: Research intended to alleviate, stabilize, or characterize the symptoms, or deficits, common to TBI and AD/ADRD.
- Family and Caregiver Support: Research intended to reduce the burden of care on the caregivers or families of individuals living with the common symptoms or deficits of TBI and AD/ADRD.
- Epidemiology: Utilize new and existing studies and datasets to examine the relationships between risk and resiliency factors for TBI and subsequent AD/ADRD.
- Novel Target Identification: Basic research (non-human) directly leading to identification of new targets for the development of existing or new investigational medicines, drugs, or agents for TBI and subsequent AD/ADRD.
- Nonpharmacological Interventions and Devices: Research into non-pharmaceutical-based interventions and devices to improve quality of life or caregiving for those living with the common symptoms of TBI and AD/ADRD.
- Bioinformatics: Tools, including machine learning, to access, annotate, curate, store, and visualize large existing or novel datasets, e.g., multimodal magnetic resonance imaging (MRI), other imaging techniques, surveys, questionnaires, and diagnostics for TBI and subsequent AD/ADRD.
International Alzheimer's Disease Research Portfolio
Dr. Michael Jaffee
University of Florida
Collaborating on Military Risk Factors for Alzheimer’s and Other Dementias
A Link between TBI and Alzheimer's Disease?
The Advocate's Perspective
Last updated Tuesday, July 21, 2020